Neuropharmacological profile of EMD 57445, a σ receptor ligand with potential antipsychotic activity

European Journal of Pharmacology

Volumn 315, Issue 3, 1996, Pages 235-243

  Maj, Jerzy ^a   Rogóz, Zofia ^a   Skuza, Grazyna ^a   Mazela, Halina ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Behavioral model; Central effect; EMD 57445; Receptor ligand; RimcazoIe

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMPHETAMINE; APOMORPHINE; CAFFEINE; COCAINE; DIZOCILPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; KAPPA OPIATE RECEPTOR; LIGAND; MORPHINE; NEUROLEPTIC AGENT; OPIATE RECEPTOR; PANAMESINE; QUINPIROLE; RIMCAZOLE; SPIPERONE; UNCLASSIFIED DRUG;

AGGRESSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; GROOMING; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; LOCOMOTION; MALE; MICE; MORPHINE; OXAZOLES; PIPERIDINES; RATS; RATS, WISTAR;

EID: 0030597312     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00602-4     Document Type: Article

References (40)

1. Bartoszyk, G.D., H.E. Greiner, J. Harting, M. Stohrer and C.A. Seyfried, 1992, Pharmacological profile of the atypical neuroleptic drug EMD 57445, Soc. Neurosci. Abstr. 18, 548.
2. Bartoszyk, G.D., H.M. Bender, A. Heusener and C. Schnorr, 1995, Pharmacology of the potential antipsychotic EMD 57445 in animals and humans, Eur. Neuropsychopharmacol. 5, 331.
3. Bartoszyk, G.D., H.M. Bender, J. Hellmann, C. Schnorr and C.A. Seyfried, 1996, EMD 57445: a selective sigma receptor ligand with the profile of an atypical neuroleptic, CNS Drug Rev. 2, 175.
4. Bejanian, M., R.N. Pechnick, M.P. Bova and R. George, 1991, Effects of subcutaneous and intracerebroventricular administration of the sigma receptor ligand 1,3-di-o-tolylguanidine on body temperature in the rat: interactions with BMY 14802 and rimcazole, J. Pharmacol. Exp. Ther. 258, 88.
5. 10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic, Eur. J. Pharmacol. 154, 53.
6. Chouinard, G. and L. Annable, 1984, An early phase II clinical trial of BW 234U in the treatment of acute schizophrenia in newly admitted patients, Psychopharmacology 84, 282.
7. Clineschmidt, B.V., G.E. Martin, P.R. Bunting and N.L. Papp, 1982, Central symphatomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympatomimetic and apparent anxiolytic properties, Drug Dev. Res. 2, 135.
8. Davidson, J., R. Miller, M. Wingfield, W. Zung and A.T. Dren, 1982, The first clinical study of BW 234U in schizophrenia, Pharmacol. Bull. 18, 176.
9. Delini-Stula, A. and C. Morpurgo, 1968, Influence of amphetamine and scopolamine on the catalepsy induced by diencephalic lesions in rats, Int. J. Neuropharmacol. 7, 391.
10. Ferris, R.M., M. Harfenist, G.M. McKezie, B. Cooper, F.E. Soroko and R.A. Maxwell, 1982, BW 234U, (cis-9-[3-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent, J. Pharm. Pharmacol. 34, 388.
11. Ferris, R.M., F.L.M. Tang, K.-J. Chang and A. Russel, 1986a, Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of sigma sites in brain, Life Sci. 38, 2329.
12. Ferris, R.M., H.L. White, F.L.M. Tang, A. Russel and M. Harfenist, 1986b, Rimcazole (BW 234U), a novel antipsychotic agent whose mechanism of action cannot be explained by a direct blockade of postsynaptic dopaminergic receptors in brain, Drug Dev. Res. 9, 171.
13. Gundlach, A.L., B.L. Largent and S.H. Snyder, 1985, Phencyclidine and σ opiate receptors in brain: biochemical and autoradiographical differentiation, Eur. J. Pharmacol. 113, 465.
14. Guy, W., G. Manov, W.H. Wilson, T.A. Ban, O.K. Fjetland, P.J. Mandberg and A.T. Drew, 1983, Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: a dose-range study, Drug Dev. 3, 245.
15. Hall, H., M. Sällemark and E. Jerning, 1986, Effects of remoxypride and some related new substituted salicylamides on rat brain receptors, Acta Pharmacol. Toxicol. 58, 61.
16. Itzhak, Y., 1988, Pharmacological specificity of some psychotomimetic and antipsychotic agents for the sigma and PCP binding sites, Life Sci. 42, 745.
17. Kolasiewicz, W., J. Baran and S. Wolfarth, 1987, Mechanographic analysis of muscle rigidity after morphine and haloperidol: a new metodological approach, Naunyn-Schmiedeberg's Arch. Pharmacol. 335, 449.
18. Largent, B.L., H. Wikstrom, A.M. Snowman and S.H. Snyder, 1988, Novel antipsychotic drugs share high affinity for σ receptors, Eur. J. Pharmacol. 155, 345.
19. Litchfield, J.T. and F. Wilcoxon, 1949, A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 96, 99.
20. Maj, J., Z. Rogóz and G. Skuza, 1991, Locomotor hyperactivity induced by MK-801 in rats, Pol. J. Pharmacol. Pharm. 43, 449.
21. Maj, J., Z. Rogóz and G. Skuza, 1993a, Influence of 1,3-di-o-tolylguanidine and rimcazole, selective sigma ligands, on apomorphine and neuroleptic effects, Pol. J. Pharmacol. 45, 327.
22. Maj, J., G. Skuza and Z. Rogóz, 1993b, Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity, J. Neural Transm. [P-D Sect.] 6, 53.
23. Maj, J., Z. Rogóz and G. Skuza, 1994, Pharmacological effects of rimcazole and 1,3-di-o-tolylguanidine, sigma receptor ligands, as potential antipsychotic agents, Eur. Neuropsychopharmacol. 4, 387.
24. Maj, J., G. Skuza and Z. Rogóz, 1995, Central effects of EMD 57445, a new sigma receptor ligand with a potential antipsychotic activity, Eur. Neuropharmacol. 5, 327.
25. Martin, W.R., C.E. Eades, J.A. Thompson and R.E. Huppler, 1976, The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol. Exp. Ther. 197, 517.
26. Mendelsohn, L.G., V. Kalra, B.G. Johnson and G.A. Kerchner, 1985, Sigma opioid receptor: characterization and co-identity with the phencyclidine receptor, J. Pharmacol. Exp. Ther. 233, 597.
27. Ögren, S.O., H. Hall, C. Köhler, O. Magnusson, L.-O. Lindbom, K. Ängeby and L. Florvall, 1984, Remoxipride, a new potential antipsychotic compound with selective antidopaminergic compound with selective antidopaminergic actions in the rat brain, Eur. J. Pharmacol. 102, 459.
28. Protais, P., J. Costentin and J.C. Schwartz, 1976, Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum, Psychopharmacology 50, 1.
29. Quirion, R., P.C. Chicheportiche, K.M. Contreras, K.M. Johnson, D. Lodge, S.W. Tam, J.H. Woods and S.R. Zukin, 1987, Classification and nomenclature of phencyclidine and sigma receptor sites, Trends Neurosci. 10, 444.
30. Quirion, R., W.D. Bowen, Y. Itzhak, J.L. Junien, J.M. Mussacchio, R.B. Rothman, T.P. Su, S.W. Tam and D.P. Taylor, 1992, A proposal on the classification of sigma binding sites, Trends Pharmacol. Sci. 13, 85.
31. Rao, T.S., H.S. Kim, J. Lehmann, L.L. Martin and P.L. Wood, 1990, Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors, Neuropharmacology 29, 225.
32. Schwarcz, G.A., A. Halaris, A. Dren and P. Manberg, 1985, Open label evaluation of the novel antipsychotic compound BW 234U in chronic schizophrenics, Drug Dev. Res. 5, 387.
33. Tam, S.W., 1983, Naloxone-inaccessible sigma receptor in rat central nervous system, Proc. Natl. Acad. Sci. USA 80, 6703.
34. 3H]haloperidol binding in guinea pig brain membranes, Proc. Natl. Acad. Sci. USA 81, 5618.
35. 2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles, J. Pharmacol. Exp. Ther. 263, 1167.
36. Taylor, D.P. and J. Dekleva, 1987, Potential antipsychotic BMY 14802 selectively binds to sigma sites, Drug Dev. Res. 11, 65.
37. Walker, J.M., W.D. Bowen, F.O. Walker, R.R. Matsumoto, B.R. De Costa and K.C. Rice, 1990, Sigma receptors: biology and function, Pharmacol. Rev. 42, 355.
38. 3H]1,3-di-o-tolylguanidine (DTG) binding sites in guinea pig brain: a comparative study, Brain Res. 581, 33.
39. 3H]tolyl)guanidine: a selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs, Proc. Natl. Acad. Sci. USA 83, 8784.
40. 3H]cyclazocine binding to multiple receptor sites, Mol. Pharmacol. 20, 246.